#USA #New York #Securities Fraud #Pomerantz LLP #Capricor Therapeutics

Pomerantz Law Firm Investigates Investor Claims Against Capricor Therapeutics

Pomerantz LLP, a nationally recognized law firm, is currently investigating claims on behalf of investors who have invested in Capricor Therapeutics, Inc. (NASDAQ: CAPR). This investigation is focused on potentially unlawful business practices conducted by Capricor and certain individuals in positions of authority within the company. Investors who have suffered losses are encouraged to reach out to the firm for further assistance.

Overview of the Situation

The investigation stems from critical announcements made by Capricor that led to significant drops in the company's stock price. On May 5, 2025, Capricor released information regarding their Biologics License Application (BLA) for deramiocel, a promising cell therapy aimed at treating patients with Duchenne muscular dystrophy (DMD) cardiomyopathy. The release indicated that the U.S. Food and Drug Administration (FDA) conferred its intention to hold an advisory committee meeting in response to their submission.

However, on the following day, the market reacted unfavorably when Capricor’s stock plummeted by $3.00 or 29.13%, ultimately closing at $7.30 per share. This marked the beginning of serious investor concerns regarding the legitimacy of Capricor’s claims and the potential repercussions on its stock performance.

Then, the situation worsened on June 20, 2025, when STAT reported that the new head of the relevant FDA unit had decided to cancel the advisory committee meeting. This cancellation was attributed to uncertainties surrounding the drug's efficacy and safety, leading to another significant price drop of $3.68, equivalent to a 30.82% decrease, bringing the stock value down to $8.26 per share.

The Role of Pomerantz LLP

With over 85 years of experience, Pomerantz LLP is well-versed in handling corporate and securities class actions. Founded by the late Abraham L. Pomerantz, often referred to as the dean of the class action bar, the firm established a reputation by championing the rights of investors negatively affected by corporate fraud and breaches of fiduciary duty.

The firm's ongoing pursuit of justice emphasizes its commitment to representing victims of securities fraud. Pomerantz LLP has successfully recovered numerous multimillion-dollar damages for their clients through diligent representation. Investors who believe they may have been misled by Capricor’s actions and are seeking recovery for their losses should consult with the firm’s lawyers to explore their options.

Taking Action

If you have invested in Capricor Therapeutics and are interested in the ongoing investigation or considering joining a class action lawsuit, contact Pomerantz LLP’s Danielle Peyton at [email protected] or call 646-581-9980. Those impacted by the decline in Capricor’s stock following these announcements may have valid claims worth pursuing.

In conclusion, with the market's recent responses to Capricor's communications and FDA interactions, Pomerantz LLP’s investigative actions highlight an essential phase for potentially affected investors. The case reflects broader concerns about transparency and reliability within the biopharmaceutical sector, which investors must remain vigilant about.

For comprehensive updates and guidance, stay connected with Pomerantz LLP as the investigation progresses. For more information on how to effectively navigate this situation, visit their website or contact a qualified representative today.